We next sought to investigate whether APOE4-induced functional deficits in PFC-like spheroids could be reversed following treatment with three clinically approved compounds used to treat the symptoms of AD in humans along with two preclinical compounds being developed for AD. Here, APOE is linked to Alzheimer disease.